University of Texas SPORE in Lung Cancer: A Collaboration Between The University of Texas Southwestern Medical Center (UTSW) and The University of Texas M. D. Anderson Cancer Center (MDACC). The strategic plan of this SPORE is to identify and understand the molecular """"""""hallmarks of lung cancer"""""""" and then translate this information into the clinic for early detection, prevention, prognosis, and the selection and/or development of new treatments for lung cancer. We have invested in several major translational research themes: identification of key lung cancer tumor suppressor genes and their development as novel therapeutics; identification of persons with an increased inherited and/or acquired risk of developing lung cancer by genetic epidemiology and early detection of respiratory epithelial genetic and epigenetic alterations; identification of abnormalities in apoptosis and invasion during lung cancer pathogenesis; understanding signaling pathways that are likely new targets for chemoprevention and therapy of lung cancer; and developing lung cancer therapies directed against telomerase. To achieve these goals, our SPORE has assembled clinicians and basic scientists including medical oncologists, thoracic surgeons, pulmonary physicians, pathologists, molecular geneticists, molecular and cell biologists, epidemiologists, behavioral and psycho-pharmacologists, biostatisticians, and experts in development of new technologies and informatics. The SPORE, brings together two major complementary strengths in lung cancer research involving UTSW and MDACC. This SPORE consists of 5 inter-related projects and 4 supporting Cores. The projects involve: 1. Translation of tumor suppressor genes into new therapeutics for lung cancer; 2. Molecular epidemiology of lung cancer: comparison of surrogate and target tissues markers; 3. Molecular pathology of lung cancer related to apoptosis and invasion and its translation into the clinic; 4.The PI3K pathway as a target for lung cancer prevention and therapy; and 5. Targeting telomerase for lung cancer therapeutics The Cores are: Administrative; Pathology & Tissue Resources; Biostatistics; and Computational Biology & Innovative Technology. All of the scientific projects are: translational in nature; focus on human lung cancer; involve clinical and basic investigators and biostatisticians; interact with the other projects; and utilize Core resources. Innovative Developmental and Career Development Projects have brought new investigators into and stimulated the SPORE that are represented in each of the major projects. We also have a developmental project dealing with new methods of smoking cessation by elucidating genetic contributions to nicotine addiction and response to pharmacological treatment of nicotine addiction. This SPORE also participates in the inter-SPORE effort of the Lung Cancer Biomarkers and Chemoprevention Consortium (LCBCC). Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA070907-09
Application #
7097443
Study Section
Special Emphasis Panel (ZCA1-GRB-V (J2))
Program Officer
Ujhazy, Peter
Project Start
1996-09-30
Project End
2008-04-30
Budget Start
2006-06-28
Budget End
2007-04-30
Support Year
9
Fiscal Year
2006
Total Cost
$2,423,934
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wang, Shidan; Chen, Alyssa; Yang, Lin et al. (2018) Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome. Sci Rep 8:10393
Gomez, Daniel Richard; Byers, Lauren Averett; Nilsson, Monique et al. (2018) Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget 9:14268-14284
Parra, Edwin R; Villalobos, Pamela; Mino, Barbara et al. (2018) Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26:83-93
Yamauchi, Mitsuo; Barker, Thomas H; Gibbons, Don L et al. (2018) The fibrotic tumor stroma. J Clin Invest 128:16-25
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113
Yi, Faliu; Yang, Lin; Wang, Shidan et al. (2018) Microvessel prediction in H&E Stained Pathology Images using fully convolutional neural networks. BMC Bioinformatics 19:64
Song, Kai; Bi, Jia-Hao; Qiu, Zhe-Wei et al. (2018) A quantitative method for assessing smoke associated molecular damage in lung cancers. Transl Lung Cancer Res 7:439-449
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
He, Min; Liu, Shanshan; Gallolu Kankanamalage, Sachith et al. (2018) The Epithelial Sodium Channel (?ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors. Transl Oncol 11:292-299
Parra, Edwin R; Villalobos, Pamela; Behrens, Carmen et al. (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6:48

Showing the most recent 10 out of 1059 publications